The Peritoneal cavity (PC) is the key metastatic site for intra-abdominal malignancies (e.g., GI tract and rectal cancer). PC sites can be used to target several other diseases where lymphatic drug delivery is desired without dumping large amounts of the drug. Till recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC), and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapy for cancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understanding of the role of drug delivery systems (DDS) in targeting drugs in the intraperitoneal (IP) cavity.
There are two main challenges one posed by IP cavity where the residence time of a small molecular weight drug (<20 kDa) is not sufficiently long to maintain therapeutic effect. This leads to frequent or continuous dosing. Another challenge is device-related or catheter-related problems, such as catheter obstruction, increased risk of infection, and bowel complications. Overall literature shows that the IP site is satisfactorily explored by clinicians but in terms of drug delivery not that much. One can see a clear-cut gap of expertise exchange between the two fields and guidelines from regulatory lawmakers on new medications.
In summary, challenges like delivery to IP cavity, tumor or organ-specific targeting, efficient tissue penetration, optimal cellular uptake and intracellular residence of a drug, biocompatibility, toxicity, etc can be easily solved by smartly designing functional drug delivery systems (both nano and micro). Nanotechnologies have always fascinated humans for several decades and are now widely explored in the biomedical field. Diverse types of nanoparticles are being explored around the world, some examples include biodegradable nanoparticles, green nanoparticles, polymeric nanoparticles, lipid nanoparticles, metal nanoparticles, graphene, carbon nanotubes, and several others. Now a day's nanoparticles are gaining interest for drug targeting of chemotherapeutic drugs, immunotherapy, and gene delivery. Whereas microparticles can be explored for delayed drug delivery to the peritoneal cavity due to relatively slow removal from IP fluid. Hydrogels or other adhesive drug delivery may help to enhance peritoneal adhesions; thereby maintaining the balance between benefit and risk. Overall, drug delivery systems are key in IP targeting. That means drug delivery specialist and clinician needs to be connected to get the best out of this route of drug administration.
The present book is a link between pharmaceutical scientists (drug formulators), clinicians, toxicologists, and regulatory experts. This book also provides a new perspective to researchers to divert or guide their research in an optimal way. Exploring Drug Delivery to the Peritoneum serves as a platform for upcoming technologies especially in the medical devices sector to face up and show potential in delivering drugs. It is a chance for commercial partners like insurance companies and the pharma industry to explore this direction.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. For the last many years, she has been working with various multinational pharmaceutical companies in technical/R&D leadership roles. Currently, she serves as a Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research at numerous national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited several trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received numerous prestigious national and international awards among them include recently received the prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting, and the role of excipients in delivery systems (www.ranjitas.com).
The Peritoneal cavity (PC) is the key metastatic site for intra-abdominal malignancies (e.g., GI tract and rectal cancer). PC sites can be used to target several other diseases where lymphatic drug delivery is desired without dumping large amounts of the drug. Until recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS), heated intraperitoneal chemotherapy (HIPEC), and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapy for cancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understanding of the role of drug delivery systems in targeting drugs in the intraperitoneal (IP) cavity. There are two main challenges posed to such therapies 1) the complexity of IP cavity and 2) the drug transport dynamics e.g., the residence time of small molecular weight drugs, the fate of delivery systems (both nano and micro), etc. The present book is a link between pharmaceutical scientists (drug formulators), clinicians, and toxicologists. This book also provides a new perspective to researchers to divert or guide their research in an optimal way. Exploring Drug Delivery to the Peritoneum serves as a platform for upcoming technologies especially in the medical devices sector to face up and show potential in delivering drugs to IP cavity. It is a chance for commercial partners like insurance companies and the pharma industry to explore the old administration route in a new way.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: Brook Bookstore On Demand, Napoli, NA, Italien
Zustand: new. Questo è un articolo print on demand. Bestandsnummer des Verkäufers MQCSC58RMN
Anzahl: Mehr als 20 verfügbar
Anbieter: moluna, Greven, Deutschland
Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Unique compilation of research-clinical-toxicity-regulatory dataUnique collection of DDS (drug delivery systems) explored till nowServes one stop information source for all stages of drug targeting research to peritoneumRanjita Sheg. Bestandsnummer des Verkäufers 842326604
Anzahl: Mehr als 20 verfügbar
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Buch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The Peritoneal cavity (PC) isthekey metastatic site for intra-abdominal malignancies (e.g.,GI tract and rectal cancer). PCsitescan be used to target several other diseases where lymphatic drug delivery is desired without dumping largeamountsofthedrug. Till recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC),and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapyforcancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understandingoftherole of drug delivery systems (DDS)intargeting drugsinthe intraperitoneal (IP)cavity.There are two main challenges one posed by IP cavity where the residence time of a small molecular weight drug (In summary, challenges like delivery to IP cavity, tumor ororgan-specifictargeting, efficient tissue penetration, optimal cellular uptake and intracellular residence of a drug, biocompatibility, toxicity,etc can be easily solved by smartly designing functional drug delivery systems (both nano and micro). Nanotechnologies have always fascinatedhumansforseveral decades and are now widely explored inthebiomedical field. Diverse types of nanoparticles are being explored around the world, some examples include biodegradable nanoparticles, green nanoparticles, polymeric nanoparticles, lipid nanoparticles, metal nanoparticles, graphene, carbon nanotubes,and several others. Now a day's nanoparticles are gaining interest for drug targeting of chemotherapeutic drugs, immunotherapy,and gene delivery. Whereas microparticles can be explored for delayed drug delivery totheperitoneal cavity due to relativelyslowremoval from IP fluid. Hydrogels or other adhesive drug delivery may help to enhance peritoneal adhesions; thereby maintaining the balance betweenbenefit and risk. Overall, drug delivery systems are key in IP targeting. That means drug delivery specialist and clinician needs to be connected to getthebest out of this route of drug administration.The presentbook is a link between pharmaceuticalscientists(drugformulators), clinicians,toxicologists,and regulatory experts. This book also providesanew perspective to researchers to divert or guide their research inanoptimal way. Exploring Drug Delivery to the Peritoneum serves as a platform for upcoming technologies especially inthemedical devices sector to face up and show potential in deliveringdrugs. It is a chance for commercial partners like insurance companies andthepharma industry to explore this direction. 244 pp. Englisch. Bestandsnummer des Verkäufers 9783031316937
Anzahl: 2 verfügbar
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Zustand: New. In English. Bestandsnummer des Verkäufers ria9783031316937_new
Anzahl: Mehr als 20 verfügbar
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - The Peritoneal cavity (PC) isthekey metastatic site for intra-abdominal malignancies (e.g.,GI tract and rectal cancer). PCsitescan be used to target several other diseases where lymphatic drug delivery is desired without dumping largeamountsofthedrug. Till recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC),and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapyforcancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understandingoftherole of drug delivery systems (DDS)intargeting drugsinthe intraperitoneal (IP)cavity.There are two main challenges one posed by IP cavity where the residence time of a small molecular weight drug (In summary, challenges like delivery to IP cavity, tumor ororgan-specifictargeting, efficient tissue penetration, optimal cellular uptake and intracellular residence of a drug, biocompatibility, toxicity,etc can be easily solved by smartly designing functional drug delivery systems (both nano and micro). Nanotechnologies have always fascinatedhumansforseveral decades and are now widely explored inthebiomedical field. Diverse types of nanoparticles are being explored around the world, some examples include biodegradable nanoparticles, green nanoparticles, polymeric nanoparticles, lipid nanoparticles, metal nanoparticles, graphene, carbon nanotubes,and several others. Now a day's nanoparticles are gaining interest for drug targeting of chemotherapeutic drugs, immunotherapy,and gene delivery. Whereas microparticles can be explored for delayed drug delivery totheperitoneal cavity due to relativelyslowremoval from IP fluid. Hydrogels or other adhesive drug delivery may help to enhance peritoneal adhesions; thereby maintaining the balance betweenbenefit and risk. Overall, drug delivery systems are key in IP targeting. That means drug delivery specialist and clinician needs to be connected to getthebest out of this route of drug administration.The presentbook is a link between pharmaceuticalscientists(drugformulators), clinicians,toxicologists,and regulatory experts. This book also providesanew perspective to researchers to divert or guide their research inanoptimal way. Exploring Drug Delivery to the Peritoneum serves as a platform for upcoming technologies especially inthemedical devices sector to face up and show potential in deliveringdrugs. It is a chance for commercial partners like insurance companies andthepharma industry to explore this direction. Bestandsnummer des Verkäufers 9783031316937
Anzahl: 1 verfügbar
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschland
Buch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The Peritoneal cavity (PC) is the key metastatic site for intra-abdominal malignancies (e.g., GI tract and rectal cancer). PC sites can be used to target several other diseases where lymphatic drug delivery is desired without dumping large amounts of the drug. Till recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC), and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapy for cancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understanding of the role of drug delivery systems (DDS) in targeting drugs in the intraperitoneal (IP) cavity.There are two main challenges one posed by IP cavity where the residence time of a small molecular weight drug (Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 252 pp. Englisch. Bestandsnummer des Verkäufers 9783031316937
Anzahl: 1 verfügbar
Anbieter: Books Puddle, Woodside, NY, USA
Zustand: New. 1st ed. 2023 edition NO-PA16APR2015-KAP. Bestandsnummer des Verkäufers 26396297670
Anzahl: 4 verfügbar
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
Zustand: New. Print on Demand. Bestandsnummer des Verkäufers 401127961
Anzahl: 4 verfügbar
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
Hardcover. Zustand: Brand New. 252 pages. 9.25x6.10x9.21 inches. In Stock. Bestandsnummer des Verkäufers x-3031316932
Anzahl: 2 verfügbar
Anbieter: Biblios, Frankfurt am main, HESSE, Deutschland
Zustand: New. PRINT ON DEMAND. Bestandsnummer des Verkäufers 18396297676
Anzahl: 4 verfügbar